1700630187
3．试述肝纤维化基因诊断与治疗的进展。
1700630188
1700630189
参考文献
1700630190
1700630191
[1] Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the third AASLD single tropic research conference. Hepotlolgy, 2007, 45(1)
:242-249.
1700630192
1700630193
[2] Gressner AM, weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cell and TGFβ1 as major player and therapeutic targets. J Cell Mol Med, 2006, 10(1)
:76-99.
1700630194
1700630195
[3] Gressner OA, weiskirchen R, Gressner AM. Evalving concepts of liver fibrogenesis provid new diagnostic and therapeutic options. Comparative Hepatology, 2007, 6(1)
:7-15.
1700630196
1700630197
[4] 蔡卫民．晚期血吸虫病肝纤维化的研究进展及治疗．见赵晓贡主编：晚期血吸虫病及其严重并发症．北京：人民卫生出版社，2006
:5-39.
1700630198
1700630199
[5] 蔡卫民．抗肝纤维化药物研究新进展．中国药学杂志，2008，43(3)
:161-164.
1700630200
1700630201
[6] 蔡卫民．认识肝纤维化与晚期血吸虫病的过去与未来．中国血吸虫病防治杂志，2008；20(3)
:235-238.
1700630202
1700630203
[7] 蔡卫民．肝纤维化研究中的若干问题．中华肝脏病杂志，2008，16(7)
:557-558.
1700630204
1700630205
[8] 蔡卫民．肝纤维化研究的回顾与展望．胃肠病与肝脏病杂志，2008，17(10)
:待发表.
1700630206
1700630207
[9] 蔡卫民．肝纤维化与肝硬化的新认识．中华临床感染病杂志，2008，1(3)
:待发表.
1700630208
1700630209
[10] Chou YC, Chen ML, Hu CP, et al. Transforming growth factor-β1 supprsses HBV replication primarily through traoscri-ptional inhibition of pregenomic RNA. Hepatology, 2007, 46(3)
:672-681.
1700630210
1700630211
[11] Elsharkawy AM, Mann DA. Nuclear fector-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology, 2007, 46(2)
:590-597.
1700630212
1700630213
[12] Bergamini C, Sgarra C, Trerotoli P, et al. Laminin-5 stimulates hepatic cellular carcinoma growth through a different of 26β4 and 23β1 integrins. Hepatology, 2007, 46(6)
:1801-1809.
1700630214
1700630215
[13] Li Z, Dranoff JA, Chan EP. Transforming growth factor-β and substorate stiffness regulate portal fibroblast activation in cultur. Ibid, 2007, 46(4)
:1246-1256.
1700630216
1700630217
[14] Zeisberg M, Yang C, Martino M, et al. Fibroblast derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem, 2007, 287
:23337-23347.
1700630218
1700630219
[15] Gorrell MD. Liver fibrosis: The hepatocytes revisited. Hepatology, 2007, 46(5)1659-1661.
1700630220
1700630221
[16] Weng HL, Wang BE, Jia JD, et al. Effect of IFN-γ on hepatic fibrosis in chronic hepatitis B virus infection: A randomized controlled study. Chin Gastroenterol Hepatol, 2005, 3(8)
:819-828.
1700630222
1700630223
[17] Weng HL, Mertens PR, Gresnner AM, et al. IFN-γ abrograters profibrogenic TGFβ signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatology, 2007, 46(1)
:295-303.
1700630224
1700630225
[18] Weng HL, Ciuclan L, Liu Y, et al. Profibrogenic TGF-β/activin preceptor-like kinase 5 signaling via CTGF expression in hepatocytes. Hepatology, 2007, 46(4)
:1257-1270.
1700630226
1700630227
[19] Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and exploring simpler markers. Hepatology, 2008, 47(2)
:455-460.
1700630228
1700630229
[20] Fontana RJ, Goodman ZD, Dienstage JL, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis. Hepatology, 2008, 47(3)
:789-789.
1700630230
1700630231
[21] Lai KKY, Kolippakkam D, Beretta L. Comprehensive and quantitative proteome profiling of the mouse liver and plasma. Heptology, 2008, 47(3)
:1043-1051.
1700630232
1700630233
[22] Morra R, Munteanu M, Bedossa P, et al. Diagnostic value of serum protein profiliny by SELD1-TOF protein-chip compared with a biochemipal marker, fibro test for the diagnosis of advenced fibrosis in patents with chronic hepatitis C. Aliment Pharmacol Ther, 2007, 15; 26(6)
:847-858.
1700630234
1700630235
[23] Wasmuth HE, Trartwein C. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Hepatology, 2007, 45(2)
:543-545.
1700630236
[
上一页 ]
[ :1.700630187e+09 ]
[
下一页 ]